{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:30:22Z","timestamp":1790400622663,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2023,1,26]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pancreatic exocrine insufficiency is a cause of malabsorption. It is generally diagnosed if faecal elastase-1 (FE-1) levels are below 200\u2009\u00b5g\/g. Pancreatic function is assumed to be normal when faecal elastase levels are &gt;500\u2009\u00b5g\/g. The significance of faecal elastase levels above 200\u2009\u00b5g\/g but less than 500\u2009\u00b5g\/g is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study reports the response to treatment in patients who had an FE-1 level between 200 and 500\u2009\u00b5g\/g.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of these 82 patients, 28 were offered pancreatic enzyme replacement therapy (PERT). A clinical response, defined as an improvement in their initial symptoms after commencing PERT, was seen in 20 patients (71%), 7 with potentially predisposing conditions and 13 with functional diarrhoea. PERT particularly abolished or improved diarrhoea, steatorrhoea and flatulence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinicians should, therefore, be aware that a trial of PERT given to patients with FE-1 levels between 200 and 500\u2009\u00b5g\/g may lead to improvement in gastrointestinal symptoms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2022-102271","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:20:25Z","timestamp":1675948825000},"page":"371-376","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["What is the significance of a faecal elastase-1 level between 200 and 500\u03bcg\/g?"],"prefix":"10.1136","volume":"14","author":[{"given":"Alok","family":"Mathew","sequence":"first","affiliation":[{"name":"Royal Derby Hospital, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8697-920X","authenticated-orcid":false,"given":"Darren","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK"},{"name":"School of Health and Social Care, Community and Health Research Unit, University of Lincoln, Lincoln, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-6352","authenticated-orcid":false,"given":"H Jervoise N","family":"Andreyev","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK"},{"name":"The Biomedical Research Centre, Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2025090709285484000_14.5.371.1","unstructured":"Alhassan O G , Samy A A . Pancreatic insufficiency. Treasure Island, FL: StatPearls Publishing, 2021."},{"key":"2025090709285484000_14.5.371.2","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3748\/wjg.v25.i20.2430","article-title":"Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency","volume":"25","author":"Layer","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2025090709285484000_14.5.371.3","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13066","article-title":"Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician","volume":"72","author":"Othman","year":"2018","journal-title":"Int J Clin Pract"},{"key":"2025090709285484000_14.5.371.4","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1016\/S1590-8658(10)60682-2","article-title":"Italian consensus guidelines for chronic pancreatitis","volume":"42 Suppl 6","author":"Frulloni","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"Suppl 6","key":"2025090709285484000_14.5.371.5","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1136\/gut.2005.065946","article-title":"Human pancreatic exocrine response to nutrients in health and disease","volume":"54 Suppl 6","author":"Keller","year":"2005","journal-title":"Gut"},{"key":"2025090709285484000_14.5.371.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0783-y"},{"key":"2025090709285484000_14.5.371.7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i42.7258"},{"key":"2025090709285484000_14.5.371.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.91"},{"key":"2025090709285484000_14.5.371.9","doi-asserted-by":"publisher","DOI":"10.1258\/000456304322664753"},{"key":"2025090709285484000_14.5.371.10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/003655201300192058","article-title":"Faecal elastase-1: lyophilization of stool samples prevents false low results in diarrhoea","volume":"36","author":"Fischer","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"2025090709285484000_14.5.371.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9852-y"},{"key":"2025090709285484000_14.5.371.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000643","article-title":"Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines","volume":"8","author":"Phillips","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"2025090709285484000_14.5.371.13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315909"},{"issue":"Suppl 34","key":"2025090709285484000_14.5.371.14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/014107689809134S07","article-title":"Pathology of pancreatic and intestinal disorders in cystic fibrosis","volume":"91 Suppl 34","author":"Wilschanski","year":"1998","journal-title":"J R Soc Med"},{"key":"2025090709285484000_14.5.371.15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/CE.S26705","article-title":"Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency","volume":"7","author":"Nakajima","year":"2012","journal-title":"Core Evid"},{"key":"2025090709285484000_14.5.371.16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1155\/2003\/515848","article-title":"Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis","volume":"17","author":"Czak\u00f3","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"2025090709285484000_14.5.371.17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/MPA.0000000000000131","article-title":"Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life","volume":"43","author":"D\u2019Haese","year":"2014","journal-title":"Pancreas"},{"key":"2025090709285484000_14.5.371.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30661.x"},{"key":"2025090709285484000_14.5.371.19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MPA.0000000000000767","article-title":"The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: a prospective cohort study","volume":"46","author":"Saito","year":"2017","journal-title":"Pancreas"},{"key":"2025090709285484000_14.5.371.20","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/MCG.0b013e31829f56e7","article-title":"A prospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor","volume":"48","author":"Sikkens","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2025090709285484000_14.5.371.21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mpg.0000228098.66583.85","article-title":"Subclinical exocrine pancreatic dysfunction resulting from decreased cholecystokinin secretion in the presence of intestinal villous atrophy","volume":"43","author":"Nousia-Arvanitakis","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025090709285484000_14.5.371.22","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2015-133262"},{"key":"2025090709285484000_14.5.371.23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2006.03206.x","article-title":"Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms?","volume":"25","author":"Leeds","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709285484000_14.5.371.24","first-page":"1191","article-title":"Ctla-4 +49 and TNF-alpha-308 gene polymorphisms in celiac patients with exocrine pancreatic insufficiency","volume":"37","author":"Licul","year":"2013","journal-title":"Coll Antropol"},{"key":"2025090709285484000_14.5.371.25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2001.00822.x"},{"key":"2025090709285484000_14.5.371.26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0016-5085(98)70562-1","article-title":"Exocrine pancreatic insufficiency in celiac disease","volume":"114","author":"Gomez","year":"1998","journal-title":"Gastroenterology"},{"key":"2025090709285484000_14.5.371.27","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178673"},{"key":"2025090709285484000_14.5.371.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05917.x"},{"key":"2025090709285484000_14.5.371.29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF02924340","article-title":"Pancreatic exocrine and endocrine function in patients with pancreas divisum and abdominal pain","volume":"6","author":"Lindstr\u00f6m","year":"1990","journal-title":"Int J Pancreatol"},{"key":"2025090709285484000_14.5.371.30","doi-asserted-by":"publisher","DOI":"10.1159\/000094564"},{"key":"2025090709285484000_14.5.371.31","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609006775"},{"key":"2025090709285484000_14.5.371.32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02798930","article-title":"Pancreatic function in chronic inflammatory bowel disease","volume":"3","author":"Angelini","year":"1988","journal-title":"Int J Pancreatol"},{"key":"2025090709285484000_14.5.371.33","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000072","article-title":"Factors that affect prevalence of small intestinal bacterial overgrowth in chronic pancreatitis: a systematic review, meta-analysis, and meta-regression","volume":"10","author":"El Kurdi","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"2025090709285484000_14.5.371.34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-4-421"},{"key":"2025090709285484000_14.5.371.35","doi-asserted-by":"publisher","DOI":"10.1080\/003655299750025958"},{"key":"2025090709285484000_14.5.371.36","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101171"},{"key":"2025090709285484000_14.5.371.37","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1046\/j.1365-2036.2001.01070.x","article-title":"Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients","volume":"15","author":"Carroccio","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709285484000_14.5.371.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00263.x"},{"key":"2025090709285484000_14.5.371.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000514","article-title":"Lower gastrointestinal symptoms are associated with worse glycemic control and quality of life in type 1 diabetes mellitus","volume":"6","author":"Leeds","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025090709285484000_14.5.371.40","doi-asserted-by":"publisher","DOI":"10.1159\/000073655"},{"key":"2025090709285484000_14.5.371.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08730.x"},{"key":"2025090709285484000_14.5.371.42","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-17867"},{"key":"2025090709285484000_14.5.371.43","doi-asserted-by":"publisher","DOI":"10.1080\/003655201750422657"},{"key":"2025090709285484000_14.5.371.44","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.708"},{"key":"2025090709285484000_14.5.371.45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MCG.0000000000001366","article-title":"Pancreatic insufficiency in patients under sorafenib treatment for hepatocellular carcinoma","volume":"55","author":"D\u00edaz-Gonz\u00e1lez","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"2025090709285484000_14.5.371.46","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1159\/000519588","article-title":"Nivolumab-induced exocrine pancreatic insufficiency","volume":"14","author":"Sweep","year":"2021","journal-title":"Case Rep Oncol"},{"key":"2025090709285484000_14.5.371.47","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2021-102013"},{"key":"2025090709285484000_14.5.371.48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/imt-2017-0126","article-title":"Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy","volume":"10","author":"Prasanna","year":"2018","journal-title":"Immunotherapy"},{"key":"2025090709285484000_14.5.371.49","doi-asserted-by":"crossref","first-page":"627612","DOI":"10.3389\/fonc.2021.627612","article-title":"Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"2025090709285484000_14.5.371.50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.46619\/Cmj.2020.3-1023","article-title":"Chronic use of long-acting somatostatin analogues (ssas) and exocrine pancreatic insufficiency (EPI) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-nets): an under-recognized adverse effect","volume":"3","author":"Saif","year":"2020","journal-title":"Cancer Med J"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2022-102271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:29:06Z","timestamp":1757262546000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2022-102271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,7]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/flgastro-2022-102271"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2022-102271","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}